Effect of Nintedanib on Progression of Systemic Sclerosis‐Associated Interstitial Lung Disease Over 100 Weeks: Data From a Randomized Controlled Trial

OBJECTIVE: In the SENSCIS trial, participants with systemic sclerosis‐associated interstitial lung disease (SSc‐ILD) were randomized to receive nintedanib or placebo until the last participant reached week 52 but for 100 weeks or less. Nintedanib reduced the rate of decline in forced vital capacity...

Descripción completa

Detalles Bibliográficos
Autores principales: Assassi, Shervin, Distler, Oliver, Allanore, Yannick, Ogura, Takashi, Varga, John, Vettori, Serena, Crestani, Bruno, Voss, Florian, Alves, Margarida, Stowasser, Susanne, Maher, Toby M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wiley Periodicals, Inc. 2022
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9555199/
https://www.ncbi.nlm.nih.gov/pubmed/35852465
http://dx.doi.org/10.1002/acr2.11483

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9555199/
https://www.ncbi.nlm.nih.gov/pubmed/35852465
http://dx.doi.org/10.1002/acr2.11483

Ejemplares similares